Characterisation of a Portuguese origin founder missense variant in MSH6.

Authors

Kenzie Melvill, Leora Witkowski, Céline Domecq, Nancy Hamel, Justin Mayers, Sofia Maia, Manuel R Teixeira, Carla Pinto, Inês Francisco, Cristina Albuquerque, Léa Guerrini-Rousseau, Olivia C Tan, Kevin McDonnell, Alexandra Capasso, George Chong, Victoria Marcus, William D Foulkes

Published in

European journal of human genetics : EJHG. Oct 09, 2026. Epub Oct 09, 2026.

Abstract

In certain populations, founder pathogenic variants are a common cause of Lynch syndrome. Here, we report the identification of a novel Portuguese founder variant, NM_000179.3 (MSH6):c.2061 T > G (p.Cys687Trp). Our study examined 14 probands and 19 additional family members who carry this variant. With one exception, haplotype data are consistent with a single origin for all heterozygotes, likely in the Leiria District of Portugal. We investigated the clinicopathological consequences of this variant and found that, as previously reported for MSH6 pathogenic variants, (a) the presence of a pathogenic variant is not reliably associated with loss of MSH6 expression or microsatellite instability and (b) endometrial cancer is the most common associated phenotype. Due to the requirement to apply the BP5 code according to ACMG criteria, the variant is classified as a variant of uncertain significance rather than likely pathogenic. Nevertheless, the balance of evidence we present here suggests that this variant is associated with an increased risk for MSH6-related Lynch syndrome tumors.

PMID:
42855583
Bibliographic data and abstract were imported from PubMed on 10 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.